CITALOPRAM HYDROBROMIDE Drug Patent Profile
✉ Email this page to a colleague
When do Citalopram Hydrobromide patents expire, and what generic alternatives are available?
Citalopram Hydrobromide is a drug marketed by Almatica, Norvium Bioscience, Aurobindo Pharma, Chartwell Molecular, Hetero Labs Ltd Iii, Hikma, Pharm Assoc, Biovail Labs Intl, Amneal Pharms Ny, Apotex, Aurobindo, Chartwell Rx, Cosette, Dr Reddys Labs Ltd, Epic Pharma, Epic Pharma Llc, Fosun Pharma, Glenmark Pharms Ltd, Heritage Pharma, Invagen Pharms, Jubilant Generics, Mylan, Natco Pharma Ltd, Roxane, Sun Pharm Inds Inc, Sun Pharm Industries, Taro, and Torrent Pharms. and is included in thirty-four NDAs.
The generic ingredient in CITALOPRAM HYDROBROMIDE is citalopram hydrobromide. There are fifty-six drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the citalopram hydrobromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Citalopram Hydrobromide
A generic version of CITALOPRAM HYDROBROMIDE was approved as citalopram hydrobromide by AUROBINDO on October 28th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CITALOPRAM HYDROBROMIDE?
- What are the global sales for CITALOPRAM HYDROBROMIDE?
- What is Average Wholesale Price for CITALOPRAM HYDROBROMIDE?
Summary for CITALOPRAM HYDROBROMIDE
Recent Clinical Trials for CITALOPRAM HYDROBROMIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
Alphacait, LLC | Phase 2 |
Pharmacology for CITALOPRAM HYDROBROMIDE
Drug Class | Serotonin Reuptake Inhibitor |
Mechanism of Action | Serotonin Uptake Inhibitors |